References
- Adams JW, Brown JH. (2001). G-proteins in growth and apoptosis: lessons from the heart. Oncogene 20:1626–34
- Billington CK, Joseph SK, Swan C, et al. (1999). Modulation of human airway smooth muscle proliferation by type 3 phosphodiesterase inhibition. Am J Physiol 276:L412–19
- Drees M, Zimmermann R, Eisenbrand G. (1993). 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53:3058–61
- Ding B, Abe J, Wei H, et al. (2005). Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469–76
- Di X, Gennings C, Bear HD, et al. (2010). Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 124:349–60
- Farahmandbeigi M, Kadivar MR. (2000). The incidence rate of registered cancer in Fars province. Iran: Disease Control Unit, Shiraz University Press
- Fisch R, Castro L, Rochais F, Leroy J. (2006). Compartmentation of cyclic nucleotide signaling in the heart: role of cyclic nucleotide phosphodiesterase. Circ Res 99:816–28
- Fu Q, Chen X, Xiang YK. (2013). Compartmentalization of beta-adrenergic signals in cardiomyocytes. Trends Cardiovasc Med 23:250–6
- Hosseini A, Sadeghian H, Parsaee H. (2011). Novel cilostamide analogs, PDE3 inhibitors, produce positive inotropic but differential lusitropic and chronotropic effects on isolated rat atria. Clin Biochem 44:645
- Jensen JT, Schwinof KM, Zelinski-Wooten MB, et al. (2002). Phosphodiesterase 3 inhibitors selectively block the spontaneous resumption of meiosis by macaque oocytes in vitro. Hum Reprod 17:2079–84
- Karl TD. (1993). 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 53:3058–61
- Koehler JA, Yusta B, Drucker DJ. (2005). The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 19:459–73
- Larson JL, Pino MV, Geiger LE, Simeone CR. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78:44–9
- Matousovic K, Tsuboi Y, Walker H, et al. (1997). Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med 130:487–95
- Mika D, Leroy J, Vandecasteele G, Fischmeister R. (2012). PDEs create local domains of cAMP signaling. J Mol Cell Cardiol 52:323–9
- Mousavi SH, Tavakkol-Afshari J, Brook A, Jafari-Anarkooli I. (2009). Role of caspases and Bax protein in saffron-induced apoptosis in MCF-7 cells. Food Chem Toxicol 47:1909–13
- Nguyen BT, Dessauer CW. (2005). Relaxin stimulates cAMP production in MCF-7 cells upon over expression of type V adenylyl cyclase. Ann N Y Acad Sci 1041:296–9
- Omori K, Kotera J. (2007). Overview of PDEs and their regulation. Circ Res 100:309–27
- Pullamsetti SS, Banat GA, Schmall A, et al. (2013). Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 32:1121–34
- Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K. (1999). The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is post transcriptionally regulated and independent of the PKA pathway. Exp Cell Res 252:211–23
- Savino JA III, Evans JF, Rabinowitz D, et al. (2006). Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol Cancer Ther 5:556–63
- Serafini P, Meckel K, Kelso M, et al. (2006). Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691–702
- Shimizu E, Kobayashi Y, Oki Y, et al. (1999). A cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells. Life Sci 64:2081–8
- Stork PJ, Schmitt JM. (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258–66
- Tedford HW, Zamponi GW. (2006). Direct G protein modulation of Cav2 calcium channels. Pharmacol Rev 58:837–62
- Toshiki S, Kazue T, Lazuyuki T, et al. (2000). Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59:347–56
- Turner NC, Wood LJ, Burns FM, et al. (1993). The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages. Br J Pharmacol 108:876–83